| 7. | Intangible Assets |
The intangible assets relate to acquired intellectual property rights.
The movements are as follows:
| 2017 | 2016 | |||||||
| (euros in thousands) | ||||||||
|
Balance as at January 1 |
||||||||
|
Historical cost |
860 | 860 | ||||||
|
Accumulated amortization |
(486 | ) | (425 | ) | ||||
|
|
|
|
|
|||||
|
Book value |
374 | 435 | ||||||
|
Capital expenditures |
— | — | ||||||
|
Amortization charge for the year |
(62 | ) | (61 | ) | ||||
|
|
|
|
|
|||||
|
Book value as at December 31 |
312 | 374 | ||||||
|
Balance as at December 31 |
||||||||
|
Historical cost |
860 | 860 | ||||||
|
Accumulated amortization |
(548 | ) | (486 | ) | ||||
|
|
|
|
|
|||||
|
Book value |
312 | 374 | ||||||
|
|
|
|
|
|||||
On January 23, 2009, the Company purchased the family of patents and future filings based on those patents, entitled “Recombinant production of mixtures of antibodies” from Crucell Holland B.V. The non-provisional filing date for this application was on July 15, 2003 and accordingly applications stemming from that patent family have an approximate economic life of 20 years from that date, not including patent term adjustment, extensions or any related doctrine. As a result, the Company is amortizing the cost over the approximate economic life of 14 years after acquisition of the patent family.